Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
Entacapone chemical structure
|2-cyano-3- (5-dihydroxyamino-3, 4-dioxo-1-cyclohexa-1,5-dienyl)- N,N-diethyl-prop-2-enamide|
|ATC code |
|Molecular weight||305.286 g/mol|
|Elimination half-life||0.4-0.7 hour|
|Excretion||90% feces, 10% urine|
|Legal status||Prescription only, unscheduled (USA)|
|Routes of administration||Oral|
Entacapone (INN) (pronounced /ˌɛntəkəˈpoʊn/, /ɛnˈtækəpoʊn/) is a catechol-O-methyl transferase inhibitor for the treatment of Parkinson's disease. When administered in conjunction with dopaminergic agents such as L-DOPA, entacapone increases the bioavailability of these compounds by facilitating their passage across the blood-brain barrier.
It is a member of the class of nitrocatechols.
The most frequent undesirable effects caused by entacapone relate to the increased effects of L-DOPA, such as involuntary movements (dyskinesias).These occur most frequently at the beginning of entacapone treatment. Others common side effects are gastrointestinal problems, including diarrhoea, nausea and abdominal pains. The substance may cause urine to turn reddish-brown. This is a harmless side effect and is not a cause for concern. In studies with entacapone, some people have reported experiencing a dry mouth.
Entacapone is developed by Orion Pharma and marketed by Novartis under the trade names Comtan and Stalevo in the United States.
Anti-parkinson drugs: dopaminergic agents (N04B)
|Dopa and derivatives|
Tolcapone, Entacapone, Budipine
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|